MUTANT CyaA POLYPEPTIDES AND POLYPEPTIDE DERIVATIVES SUITABLE FOR THE DELIVERY OF IMMUNOGENIC MOLECULES INTO A CELL

0469250 - MBÚ 2017 RIV eng P - Patent Document
Šebo, Peter - Osičková, Adriana - Mašín, Jiří - Fayolle, C. - Krůšek, Jan - Basler, Marek - Leclerc, C. - Osička, Radim
MUTANT CyaA POLYPEPTIDES AND POLYPEPTIDE DERIVATIVES SUITABLE FOR THE DELIVERY OF IMMUNOGENIC MOLECULES INTO A CELL.
2016. Owner: Institut Pasteur (FR)- Fyziologický ústav AV ČR,v. v. i.- Mikrobiologický ústav AV ČR, v. v. i. Date of the patent acceptance: 09.11.2016. Patent Number: EP2411513
R&D Projects: GA ČR GA310/08/0447; GA MŠMT 2B06161
Institutional support: RVO:61388971 ; RVO:67985823
Keywords : Bordetella pertusis * adenylate cyclase protein
Subject RIV: EE - Microbiology, Virology; ED - Physiology (FGU-C)
https://worldwide.espacenet.com/publicationDetails/originalDocument?FT=D&date=20161109&DB=&locale=en_EP&CC=EP&NR=2411513B1&KC=B1&ND=4#

The invention relates to mutant CyaA/E570Q+K860 polypeptides suitable for use as proteinaceous vectors for delivering one or more molecules of interest into a cell, in particular into a cell expressing the CD11b receptor. The invention further relates to polypeptide derivatives suitable for eliciting an immune response in a host. The invention is more particularly directed to polypeptides derived from an adenylate cyclase protein (CyaA) either under the form of a toxin or of a toxoid, which are mutant polypeptides. Said mutant polypeptides are capable of retaining the binding activity of native CyaA to a target cell and preferably of also retaining the translocating activity of native CyaA through its N-terminal domain into target cells and furthermore have a pore-forming activity which is reduced or suppressed as compared to that of the native CyaA toxin.
Permanent Link: http://hdl.handle.net/11104/0267339